Cargando…
The Prognostic Effect of CDKN2A/2B Gene Deletions in Pediatric Acute Lymphoblastic Leukemia (ALL): Independent Prognostic Significance in BFM-Based Protocols
One of the most frequent genes affected in pediatric ALL is the CDKN2A/2B gene, acting as a secondary cooperating event and playing an important role in cell-cycle regulation and chemosensitivity. Despite its inclusion in combined CNA (copy-number alterations) classifiers, like the IKZF1plus entity...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10178600/ https://www.ncbi.nlm.nih.gov/pubmed/37174980 http://dx.doi.org/10.3390/diagnostics13091589 |
_version_ | 1785040904046772224 |
---|---|
author | Ampatzidou, Mirella Papadhimitriou, Stefanos I. Paisiou, Anna Paterakis, Georgios Tzanoudaki, Marianna Papadakis, Vassilios Florentin, Lina Polychronopoulou, Sophia |
author_facet | Ampatzidou, Mirella Papadhimitriou, Stefanos I. Paisiou, Anna Paterakis, Georgios Tzanoudaki, Marianna Papadakis, Vassilios Florentin, Lina Polychronopoulou, Sophia |
author_sort | Ampatzidou, Mirella |
collection | PubMed |
description | One of the most frequent genes affected in pediatric ALL is the CDKN2A/2B gene, acting as a secondary cooperating event and playing an important role in cell-cycle regulation and chemosensitivity. Despite its inclusion in combined CNA (copy-number alterations) classifiers, like the IKZF1plus entity and the UKALL CNA profile, the prognostic impact of the individual gene deletions outside the context of a combined CNA evaluation remains controversial. Addressing the CDKN2A/2B deletions’ additive prognostic effect in current risk-stratification algorithms, we present a retrospective study of a Greek pediatric ALL cohort comprising 247 patients studied over a 24-year period (2000–2023). Herein, we provide insight regarding the correlation with disease features, MRD clearance, and independent prognostic significance for this ALL cohort treated with contemporary BFM-based treatment protocols. Within an extended follow-up time of 135 months, the presence of the CDKN2A/2B deletions (biallelic or monoallelic) was associated with inferior EFS rates (65.1% compared to 91.8% for the gene non-deleted subgroup, p < 0.001), with the relapse rate accounting for 22.2% and 5.9%, respectively (p < 0.001). The presence of the biallelic deletion was associated with the worst outcomes (EFS 57.2% vs. 89.6% in the case of any other status, monoallelic or non-deleted, p < 0.001). Survival differences were demonstrated for B-ALL cases (EFS 65.3% vs. 93.6% for the non-deleted B-ALL subgroup, p < 0.001), but the prognostic effect was not statistically significant within the T-ALL cohort (EFS 64.3 vs. 69.2, p = 0.947). The presence of the CDKN2A/2B deletions clearly correlated with inferior outcomes within all protocol-defined risk groups (standard risk (SR): EFS 66.7% vs. 100%, p < 0.001, intermediate risk (IR): EFS 77.1% vs. 97.9%, p < 0.001, high risk (HR): EFS 42.1% vs. 70.5% p < 0.001 for deleted vs non-deleted cases in each patient risk group); additionally, in this study, the presence of the deletion differentiated prognosis within both MRD-positive and -negative subgroups on days 15 and 33 of induction. In multivariate analysis, the presence of the CDKN2A/2B deletions was the most important prognostic factor for relapse and overall survival, yielding a hazard ratio of 5.2 (95% confidence interval: 2.59–10.41, p < 0.001) and 5.96 (95% confidence interval: 2.97–11.95, p < 0.001), respectively, designating the alteration’s independent prognostic significance in the context of modern risk stratification. The results of our study demonstrate that the presence of the CDKN2A/2B deletions can further stratify all existing risk groups, identifying patient subgroups with different outcomes. The above biallelic deletions could be incorporated into future risk-stratification algorithms, refining MRD-based stratification. In the era of targeted therapies, future prospective controlled clinical trials will further explore the possible use of cyclin-dependent kinase inhibitors (CDKIs) in CDKN2A/2B-affected ALL pediatric subgroups. |
format | Online Article Text |
id | pubmed-10178600 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-101786002023-05-13 The Prognostic Effect of CDKN2A/2B Gene Deletions in Pediatric Acute Lymphoblastic Leukemia (ALL): Independent Prognostic Significance in BFM-Based Protocols Ampatzidou, Mirella Papadhimitriou, Stefanos I. Paisiou, Anna Paterakis, Georgios Tzanoudaki, Marianna Papadakis, Vassilios Florentin, Lina Polychronopoulou, Sophia Diagnostics (Basel) Article One of the most frequent genes affected in pediatric ALL is the CDKN2A/2B gene, acting as a secondary cooperating event and playing an important role in cell-cycle regulation and chemosensitivity. Despite its inclusion in combined CNA (copy-number alterations) classifiers, like the IKZF1plus entity and the UKALL CNA profile, the prognostic impact of the individual gene deletions outside the context of a combined CNA evaluation remains controversial. Addressing the CDKN2A/2B deletions’ additive prognostic effect in current risk-stratification algorithms, we present a retrospective study of a Greek pediatric ALL cohort comprising 247 patients studied over a 24-year period (2000–2023). Herein, we provide insight regarding the correlation with disease features, MRD clearance, and independent prognostic significance for this ALL cohort treated with contemporary BFM-based treatment protocols. Within an extended follow-up time of 135 months, the presence of the CDKN2A/2B deletions (biallelic or monoallelic) was associated with inferior EFS rates (65.1% compared to 91.8% for the gene non-deleted subgroup, p < 0.001), with the relapse rate accounting for 22.2% and 5.9%, respectively (p < 0.001). The presence of the biallelic deletion was associated with the worst outcomes (EFS 57.2% vs. 89.6% in the case of any other status, monoallelic or non-deleted, p < 0.001). Survival differences were demonstrated for B-ALL cases (EFS 65.3% vs. 93.6% for the non-deleted B-ALL subgroup, p < 0.001), but the prognostic effect was not statistically significant within the T-ALL cohort (EFS 64.3 vs. 69.2, p = 0.947). The presence of the CDKN2A/2B deletions clearly correlated with inferior outcomes within all protocol-defined risk groups (standard risk (SR): EFS 66.7% vs. 100%, p < 0.001, intermediate risk (IR): EFS 77.1% vs. 97.9%, p < 0.001, high risk (HR): EFS 42.1% vs. 70.5% p < 0.001 for deleted vs non-deleted cases in each patient risk group); additionally, in this study, the presence of the deletion differentiated prognosis within both MRD-positive and -negative subgroups on days 15 and 33 of induction. In multivariate analysis, the presence of the CDKN2A/2B deletions was the most important prognostic factor for relapse and overall survival, yielding a hazard ratio of 5.2 (95% confidence interval: 2.59–10.41, p < 0.001) and 5.96 (95% confidence interval: 2.97–11.95, p < 0.001), respectively, designating the alteration’s independent prognostic significance in the context of modern risk stratification. The results of our study demonstrate that the presence of the CDKN2A/2B deletions can further stratify all existing risk groups, identifying patient subgroups with different outcomes. The above biallelic deletions could be incorporated into future risk-stratification algorithms, refining MRD-based stratification. In the era of targeted therapies, future prospective controlled clinical trials will further explore the possible use of cyclin-dependent kinase inhibitors (CDKIs) in CDKN2A/2B-affected ALL pediatric subgroups. MDPI 2023-04-28 /pmc/articles/PMC10178600/ /pubmed/37174980 http://dx.doi.org/10.3390/diagnostics13091589 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Ampatzidou, Mirella Papadhimitriou, Stefanos I. Paisiou, Anna Paterakis, Georgios Tzanoudaki, Marianna Papadakis, Vassilios Florentin, Lina Polychronopoulou, Sophia The Prognostic Effect of CDKN2A/2B Gene Deletions in Pediatric Acute Lymphoblastic Leukemia (ALL): Independent Prognostic Significance in BFM-Based Protocols |
title | The Prognostic Effect of CDKN2A/2B Gene Deletions in Pediatric Acute Lymphoblastic Leukemia (ALL): Independent Prognostic Significance in BFM-Based Protocols |
title_full | The Prognostic Effect of CDKN2A/2B Gene Deletions in Pediatric Acute Lymphoblastic Leukemia (ALL): Independent Prognostic Significance in BFM-Based Protocols |
title_fullStr | The Prognostic Effect of CDKN2A/2B Gene Deletions in Pediatric Acute Lymphoblastic Leukemia (ALL): Independent Prognostic Significance in BFM-Based Protocols |
title_full_unstemmed | The Prognostic Effect of CDKN2A/2B Gene Deletions in Pediatric Acute Lymphoblastic Leukemia (ALL): Independent Prognostic Significance in BFM-Based Protocols |
title_short | The Prognostic Effect of CDKN2A/2B Gene Deletions in Pediatric Acute Lymphoblastic Leukemia (ALL): Independent Prognostic Significance in BFM-Based Protocols |
title_sort | prognostic effect of cdkn2a/2b gene deletions in pediatric acute lymphoblastic leukemia (all): independent prognostic significance in bfm-based protocols |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10178600/ https://www.ncbi.nlm.nih.gov/pubmed/37174980 http://dx.doi.org/10.3390/diagnostics13091589 |
work_keys_str_mv | AT ampatzidoumirella theprognosticeffectofcdkn2a2bgenedeletionsinpediatricacutelymphoblasticleukemiaallindependentprognosticsignificanceinbfmbasedprotocols AT papadhimitrioustefanosi theprognosticeffectofcdkn2a2bgenedeletionsinpediatricacutelymphoblasticleukemiaallindependentprognosticsignificanceinbfmbasedprotocols AT paisiouanna theprognosticeffectofcdkn2a2bgenedeletionsinpediatricacutelymphoblasticleukemiaallindependentprognosticsignificanceinbfmbasedprotocols AT paterakisgeorgios theprognosticeffectofcdkn2a2bgenedeletionsinpediatricacutelymphoblasticleukemiaallindependentprognosticsignificanceinbfmbasedprotocols AT tzanoudakimarianna theprognosticeffectofcdkn2a2bgenedeletionsinpediatricacutelymphoblasticleukemiaallindependentprognosticsignificanceinbfmbasedprotocols AT papadakisvassilios theprognosticeffectofcdkn2a2bgenedeletionsinpediatricacutelymphoblasticleukemiaallindependentprognosticsignificanceinbfmbasedprotocols AT florentinlina theprognosticeffectofcdkn2a2bgenedeletionsinpediatricacutelymphoblasticleukemiaallindependentprognosticsignificanceinbfmbasedprotocols AT polychronopoulousophia theprognosticeffectofcdkn2a2bgenedeletionsinpediatricacutelymphoblasticleukemiaallindependentprognosticsignificanceinbfmbasedprotocols AT ampatzidoumirella prognosticeffectofcdkn2a2bgenedeletionsinpediatricacutelymphoblasticleukemiaallindependentprognosticsignificanceinbfmbasedprotocols AT papadhimitrioustefanosi prognosticeffectofcdkn2a2bgenedeletionsinpediatricacutelymphoblasticleukemiaallindependentprognosticsignificanceinbfmbasedprotocols AT paisiouanna prognosticeffectofcdkn2a2bgenedeletionsinpediatricacutelymphoblasticleukemiaallindependentprognosticsignificanceinbfmbasedprotocols AT paterakisgeorgios prognosticeffectofcdkn2a2bgenedeletionsinpediatricacutelymphoblasticleukemiaallindependentprognosticsignificanceinbfmbasedprotocols AT tzanoudakimarianna prognosticeffectofcdkn2a2bgenedeletionsinpediatricacutelymphoblasticleukemiaallindependentprognosticsignificanceinbfmbasedprotocols AT papadakisvassilios prognosticeffectofcdkn2a2bgenedeletionsinpediatricacutelymphoblasticleukemiaallindependentprognosticsignificanceinbfmbasedprotocols AT florentinlina prognosticeffectofcdkn2a2bgenedeletionsinpediatricacutelymphoblasticleukemiaallindependentprognosticsignificanceinbfmbasedprotocols AT polychronopoulousophia prognosticeffectofcdkn2a2bgenedeletionsinpediatricacutelymphoblasticleukemiaallindependentprognosticsignificanceinbfmbasedprotocols |